Loading...
Docoh

Ainos (AIMD)

Amarillo Biosciences, Inc. (ABI) is a diversified healthcare company engaged in the discovery and development of pharmaceutical and biotech products. Our goal is to introduce novel products that actively stimulate and rejuvenate the human body to combat disease and enhance the ability to heal. We engage in the advancement of low-dose non-injectable interferon as a therapeutic treatment for numerous indications such as thrombocytopenia, Sjögren’s syndrome, hepatitis C virus (HCV) and influenza. ABI primarily operates through three divisions: Pharmaceutical, Medical and Consumer. The Pharmaceutical division leverages a proprietary library of over a hundred scientific and clinical data studies on various human and animal applications of low-dose interferon, for patent licensing and commercialization opportunities with global partners. The Medical division is focused on developing an innovative, state-of-the-art technology to treat metabolism related diseases such as Type 1 and Type 2 diabetes in Asia. The Consumer division includes a range of nutraceutical and food supplement products that utilize our unique liposomal delivery systems. ABI currently has offices in the United States and Taiwan.

Company profile

AIMD stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

16 May 22
9 Aug 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.87M 1.87M 1.87M 1.87M 1.87M 1.87M
Cash burn (monthly) (no burn) (no burn) 694.35K 132.79K 463.3K 202.34K
Cash used (since last report) n/a n/a 2.99M 571.78K 1.99M 871.25K
Cash remaining n/a n/a -1.12M 1.3M -123.51K 1M
Runway (months of cash) n/a n/a -1.6 9.8 -0.3 4.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
28 Jul 22 Hui-Lan Wu RSU Common Stock Grant Acquire A No No 0 2,000,000 0 2,000,000
28 Jul 22 chun-hsien tsai RSU Common Stock Grant Acquire A No No 0 5,000,000 0 5,000,000
28 Jul 22 chung-yi tsai RSU Common Stock Grant Acquire A No No 0 330,000 0 330,000
28 Jul 22 yao-chung chiang RSU Common Stock Grant Acquire A No No 0 330,000 0 330,000
28 Jul 22 wen-han chang RSU Common Stock Grant Acquire A No No 0 330,000 0 330,000
31 Mar 22 Hui-Lan Wu Convertible Note Common Stock Grant Acquire A Yes No 1 50,000 50K 50,000
69.3% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 1 1
Opened positions 0 1 EXIT
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 50M 50M
Total shares 100M 100M
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Ainos 100M $50M 0.0%
Largest transactions Shares Bought/sold Change
Ainos 100M 0 0.0%

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: acid, acquisition, adjustment, aka, APA, Attorney, automatically, borrowing, Calibre, Chain, CICCT, collaboration, collaborator, concentrated, correct, covid, cumulative, daughter, default, delegating, delegation, depreciation, diversification, draft, driven, duty, edgar, eighty, enumerated, EUA, exhaust, fail, female, Footnote, forecast, foresee, GAAP, grew, guarantee, harbor, hereof, holder, Hsu, implied, imprecise, incorrect, InnoPharmax, IP, IXBRL, Liao, met, modified, narrative, noninterest, notice, nucleic, obligation, offset, outlook, Oxley, parallel, pathway, percent, Polymerase, preferred, prioritizing, publicly, RBD, Reaction, recruit, Reform, remediate, remediation, repaid, repayment, seamlessly, sooner, Taiwanese, threshold, Top, turn, unforeseen, unknown, upcoming, version, Virgin, worse
Removed: abroad, academic, accurately, achieving, acquire, activation, actively, advancing, advantage, advertising, Advisor, affecting, alternative, Alternatively, amendment, animal, antitrust, applicant, applying, appointed, approximately, Asia, assessing, assist, assure, attached, attestation, bacterial, begin, beneficial, Bernard, biotech, biotechnology, branch, cancer, candidate, canker, carefully, cell, CFR, Chairman, characterized, chemically, Chen, china, choose, Chrystal, civil, claimed, classified, cleared, climate, closely, Cohen, commence, compare, compete, competition, competitive, complex, complexity, comply, composition, comprehensive, consultant, consummation, content, continually, convey, corrupt, Cosmetic, costly, country, criminal, cultural, currency, custom, cytotoxic, damage, deficit, define, delivery, demonstrate, demonstration, designation, determined, developed, diagnostic, difficult, difficulty, digital, diminish, discovery, discussed, disruption, distance, distributing, diversion, division, Documented, Dr, economic, economically, effect, efficacy, enacted, enforcement, engineered, enhance, environment, equivalence, Esq, established, ethical, evaluating, evolving, exceed, exempt, expanding, experience, experienced, Expiration, explore, exploring, export, expose, fabrication, face, facilitate, facility, Failure, feasible, fewer, firm, focusing, food, foreign, formal, forward, framework, gain, genetically, genital, Geographic, geopolitical, global, govern, governing, governmental, grant, greater, greatly, group, hardware, healthy, helicobacter, hereto, high, human, identify, iii, imitate, immune, impairment, impede, importance, improved, inability, IND, independent, industry, infection, influenza, informal, infusion, inherently, injury, innovative, inspection, insulin, insure, integrated, intelligence, intense, intravenously, invention, investigational, John, judgment, judiciously, June, Junyong, labeling, labor, laboratory, lack, language, large, Lawrence, legally, legislative, level, leverage, library, licensing, life, likelihood, limit, limited, Lin, LLC, local, location, longer, lower, manager, managing, manner, marketed, matter, media, metabolic, method, model, monetary, month, monthly, nationalization, natural, nature, NDA, negatively, newer, nutraceutical, obtained, October, offered, operate, operated, operational, opposed, orphan, ownership, patent, path, pending, performed, permit, person, physical, PMA, political, precedent, predecessor, predicate, premarket, present, presently, prevent, preventing, pricing, privacy, Procuring, produce, producer, production, prohibiting, promoting, promotion, promulgated, proposed, publicity, pulsatile, pump, pursuing, pylori, quality, rapidly, rare, recapitalization, received, recognize, record, recoup, registered, regularly, regulate, regulated, reimbursement, repatriation, reputation, require, resource, restoration, restricted, restrictive, retained, rigidity, risky, role, route, safety, satisfy, satisfying, scaling, scientific, scientifically, scope, Secretary, secure, selected, September, serve, service, Shelton, shorten, shorter, situation, smart, software, source, sourcing, Sponsoring, state, steadily, Stephen, stockholder, storage, strain, Submission, submit, succeed, superiority, supplement, supply, synthesized, system, technical, technological, temporary, terminated, terrorism, threatened, timeframe, trade, traditional, Treadway, treat, typical, unanticipated, undergo, Unfavorable, unique, United, unpredictable, unreasonable, unsuccessful, utility, utilize, variety, vary, varying, volume, war, wide, worked, workforce, written